Rapport Therapeutics, Inc. Operating Cash Flow
Rapport Therapeutics, Inc. (RAPP) reported Operating Cash Flow of -$54.52 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$41.45M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$13.06M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$24.70M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$17.46M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$87.47M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$64.83M.
- Rapport Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$27.18M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$41.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$54.52M 10-Q · filed 2026-08-05 | -$79.22M derived: sum of 3 quarters · filed 2026-08-05 | -$96.68M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$13.06M 10-Q · filed 2026-05-07 | -$37.76M derived: sum of 2 quarters · filed 2026-05-07 | -$55.23M derived: sum of 3 quarters · filed 2026-05-07 | -$80.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$24.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$42.17M derived: sum of 2 quarters · filed 2026-03-10 | -$67.24M derived: sum of 3 quarters · filed 2026-08-05 | -$87.47M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$17.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$42.53M derived: sum of 2 quarters · filed 2026-08-05 | -$62.77M 10-Q · filed 2025-11-06 | -$77.22M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$25.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$45.31M 10-Q · filed 2026-08-05 | -$59.75M derived: sum of 3 quarters · filed 2026-08-05 | -$76.17M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$20.24M 10-Q · filed 2026-05-07 | -$34.68M derived: sum of 2 quarters · filed 2026-05-07 | -$51.10M derived: sum of 3 quarters · filed 2026-05-07 | -$67.45M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$14.45M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$30.86M derived: sum of 2 quarters · filed 2026-03-10 | -$47.21M derived: sum of 3 quarters · filed 2026-03-10 | -$64.83M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$16.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$32.77M derived: sum of 2 quarters · filed 2025-11-06 | -$50.38M 10-Q · filed 2025-11-06 | -$60.74M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$16.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$33.97M 10-Q · filed 2025-08-07 | -$44.32M derived: sum of 3 quarters · filed 2025-08-07 | -$49.75M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$17.61M 10-Q · filed 2025-05-08 | -$27.97M derived: sum of 2 quarters · filed 2025-05-08 | -$33.40M derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | -$15.78M derived: sum of 2 quarters · filed 2025-03-11 | -$27.18M 10-K · filed 2025-03-11 | |
| 2023-09-30 | -$5.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$16.82M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$11.40M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |